Sangeetha Venugopal, MD, MS, discussed the evolving landscape of acute myeloid leukemia treatment as well as unmet needs ...

According to researchers at The University of Texas MD Anderson Cancer Center, 80% of patients with previously untreated or ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the Investigational New ...

Last November, longtime Claremont resident Lou Berrio was diagnosed with acute myeloid leukemia, a type of cancer that tricks ...

According to researchers at The University of Texas MD Anderson Cancer Center, 80% of patients with previously untreated or ...

A four-year, $1.2 million grant from the National Cancer Institute of the National Institutes of Health may help researchers ...

Ongoing research is exploring new molecular targets and targeted therapies for this challenging disease.

Venetoclax is under clinical development by AbbVie and currently in Phase II for Secondary Acute Myeloid Leukemia.

BYON-4413 is under clinical development by Byondis and currently in Phase I for Refractory Acute Myeloid Leukemia.

Exploring the triple combination with venetoclax and azacitidineStudy sponsored by Oregon Health & Science University (OHSU)MADRID and ...

According to new research, 80% of patients with previously untreated or relapsed/refractory advanced-phase chronic myeloid leukemia (CML) -- including both accelerated or myeloid blast phases of the ...